Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103201965> ?p ?o ?g. }
- W2103201965 endingPage "81" @default.
- W2103201965 startingPage "76" @default.
- W2103201965 abstract "The present multicenter phase II study evaluated the efficacy and safety of weekly docetaxel as second-line chemotherapy for metastatic urothelial carcinoma. Weekly docetaxel was well tolerated but demonstrated modest activity, with a response rate of 6%, a median progression-free survival (PFS) of 1.4 months, and a median overall survival (OS) of 8.3 months. The dichotomy between PFS and OS was likely associated with subsequent platinum-based chemotherapy received by 58% of the patients.Docetaxel is commonly used for second-line therapy for metastatic urothelial carcinoma (UC). However, myelosuppression is a substantial concern when the traditional 3-week docetaxel cycle is used. The present multicenter phase II study evaluated the efficacy and safety of weekly docetaxel as second-line chemotherapy for metastatic UC.Patients with progression after previous platinum-based chemotherapy for advanced or metastatic disease were treated with docetaxel 30 mg/m(2) on days 1 and 8 every 21 days. The primary endpoint was the response rate.The study enrolled 31 patients. Their median age was 64 years (range, 40-79 years). An Eastern Cooperative Oncology Group performance status of 1, liver metastasis, and a hemoglobin level < 10 g/dL were observed in 100%, 32%, and 23% of patients, respectively. Previous platinum-based chemotherapy had been administered for metastatic disease in 29 patients (94%). Although fatigue (13%) and anorexia (6%) were the most frequently observed grade 3 to 4 toxicities, the safety profiles were generally mild and manageable. Two patients (6%) achieved an objective response, which was maintained for 3.0 to 7.8 months. Eight patients experienced disease stabilization (disease control rate, 32%). The median progression-free survival (PFS) and overall survival (OS) were 1.4 months (95% confidence interval [CI], 1.3-1.6) and 8.3 months (95% CI, 5.9-10.6), respectively. A relatively long OS was associated with further salvage platinum-based chemotherapy (n = 18, 58%) showing an encouraging activity (response rate, 44%; median PFS, 4.0 months).Second-line chemotherapy with weekly docetaxel was well tolerated but demonstrated modest activity in patients with metastatic UC. A platinum-based combination as second-line treatment might be considered for selected patients." @default.
- W2103201965 created "2016-06-24" @default.
- W2103201965 creator A5011928803 @default.
- W2103201965 creator A5015598872 @default.
- W2103201965 creator A5019406140 @default.
- W2103201965 creator A5030926405 @default.
- W2103201965 creator A5035019823 @default.
- W2103201965 creator A5043919045 @default.
- W2103201965 creator A5057146015 @default.
- W2103201965 creator A5066094957 @default.
- W2103201965 creator A5067818349 @default.
- W2103201965 date "2016-02-01" @default.
- W2103201965 modified "2023-09-25" @default.
- W2103201965 title "A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma" @default.
- W2103201965 cites W1638630979 @default.
- W2103201965 cites W1858135205 @default.
- W2103201965 cites W1971208896 @default.
- W2103201965 cites W1994192011 @default.
- W2103201965 cites W2008466182 @default.
- W2103201965 cites W2040377946 @default.
- W2103201965 cites W2053432470 @default.
- W2103201965 cites W2065870674 @default.
- W2103201965 cites W2069624577 @default.
- W2103201965 cites W2100139252 @default.
- W2103201965 cites W2102116016 @default.
- W2103201965 cites W2102880631 @default.
- W2103201965 cites W2103257412 @default.
- W2103201965 cites W2105737543 @default.
- W2103201965 cites W2123528875 @default.
- W2103201965 cites W2124631985 @default.
- W2103201965 cites W2126583945 @default.
- W2103201965 cites W2133297657 @default.
- W2103201965 cites W2145118120 @default.
- W2103201965 cites W2147075384 @default.
- W2103201965 cites W2152194109 @default.
- W2103201965 cites W2152334952 @default.
- W2103201965 cites W2157244703 @default.
- W2103201965 cites W2165542862 @default.
- W2103201965 cites W2261061094 @default.
- W2103201965 cites W2465221794 @default.
- W2103201965 cites W2471713024 @default.
- W2103201965 cites W2598118595 @default.
- W2103201965 cites W4233628679 @default.
- W2103201965 cites W4246715702 @default.
- W2103201965 doi "https://doi.org/10.1016/j.clgc.2015.09.008" @default.
- W2103201965 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26454620" @default.
- W2103201965 hasPublicationYear "2016" @default.
- W2103201965 type Work @default.
- W2103201965 sameAs 2103201965 @default.
- W2103201965 citedByCount "12" @default.
- W2103201965 countsByYear W21032019652016 @default.
- W2103201965 countsByYear W21032019652017 @default.
- W2103201965 countsByYear W21032019652018 @default.
- W2103201965 countsByYear W21032019652019 @default.
- W2103201965 countsByYear W21032019652022 @default.
- W2103201965 countsByYear W21032019652023 @default.
- W2103201965 crossrefType "journal-article" @default.
- W2103201965 hasAuthorship W2103201965A5011928803 @default.
- W2103201965 hasAuthorship W2103201965A5015598872 @default.
- W2103201965 hasAuthorship W2103201965A5019406140 @default.
- W2103201965 hasAuthorship W2103201965A5030926405 @default.
- W2103201965 hasAuthorship W2103201965A5035019823 @default.
- W2103201965 hasAuthorship W2103201965A5043919045 @default.
- W2103201965 hasAuthorship W2103201965A5057146015 @default.
- W2103201965 hasAuthorship W2103201965A5066094957 @default.
- W2103201965 hasAuthorship W2103201965A5067818349 @default.
- W2103201965 hasConcept C121608353 @default.
- W2103201965 hasConcept C126322002 @default.
- W2103201965 hasConcept C143998085 @default.
- W2103201965 hasConcept C203092338 @default.
- W2103201965 hasConcept C2776694085 @default.
- W2103201965 hasConcept C2778822529 @default.
- W2103201965 hasConcept C2779013556 @default.
- W2103201965 hasConcept C2779984678 @default.
- W2103201965 hasConcept C2780352672 @default.
- W2103201965 hasConcept C2780739268 @default.
- W2103201965 hasConcept C2781190966 @default.
- W2103201965 hasConcept C2911057145 @default.
- W2103201965 hasConcept C3019882237 @default.
- W2103201965 hasConcept C31760486 @default.
- W2103201965 hasConcept C535046627 @default.
- W2103201965 hasConcept C71924100 @default.
- W2103201965 hasConceptScore W2103201965C121608353 @default.
- W2103201965 hasConceptScore W2103201965C126322002 @default.
- W2103201965 hasConceptScore W2103201965C143998085 @default.
- W2103201965 hasConceptScore W2103201965C203092338 @default.
- W2103201965 hasConceptScore W2103201965C2776694085 @default.
- W2103201965 hasConceptScore W2103201965C2778822529 @default.
- W2103201965 hasConceptScore W2103201965C2779013556 @default.
- W2103201965 hasConceptScore W2103201965C2779984678 @default.
- W2103201965 hasConceptScore W2103201965C2780352672 @default.
- W2103201965 hasConceptScore W2103201965C2780739268 @default.
- W2103201965 hasConceptScore W2103201965C2781190966 @default.
- W2103201965 hasConceptScore W2103201965C2911057145 @default.
- W2103201965 hasConceptScore W2103201965C3019882237 @default.
- W2103201965 hasConceptScore W2103201965C31760486 @default.
- W2103201965 hasConceptScore W2103201965C535046627 @default.
- W2103201965 hasConceptScore W2103201965C71924100 @default.